Adeno-associated virus (AAV)-based gene therapy has been demonstrated to be extremely
effective for treating genetic hearing loss over the past several years. However, successful …

Mice lacking the vesicular glutamate transporter-3 (VGLUT3) are congenitally deaf due to
loss of glutamate release at the inner hair cell afferent synapse. Cochlear delivery of …

Cochlear gene therapy has made tremendous strides over the past 5 years. The first study
documenting successful restoration of congenital hearing loss using AAV-mediated gene …

AAV-mediated gene therapy is a promising approach for treating genetic hearing loss.
Replacement or editing of the Tmc1 gene, encoding hair cell mechanosensory ion channels …

The cochlea consists of multiple types of cells, including hair cells, supporting cells and
spiral ganglion neurons, and is responsible for converting mechanical forces into electric …

Adeno-associated virus (AAV) has been successfully used to deliver gene therapy to
improve auditory function in mouse models of hereditary hearing loss. Many forms of …

Inner ear gene therapy using adeno-associated viruses (AAVs) has been successfully
applied to several mouse models of hereditary hearing loss to improve their auditory …

Gene therapy for auditory diseases is gradually maturing. Recent progress in gene therapy
treatments for genetic and acquired hearing loss has demonstrated the feasibility in animal …

Gene therapy, used to achieve functional recovery from sensorineural deafness, promises to
grant better understanding of the underlying molecular and genetic mechanisms that …

Inner ear gene therapy using adeno-associated viral vectors (AAVs) in neonatal mice can
alleviate hearing loss in mouse models of deafness. However, efficient and safe transgene …